Physician profile
James C Hardwick
NPI 1437130911
$5,575.36
in general payments reported to CMS, 2019-2025
31 companies · $642 in 2025
The $642 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $784 · 2020: $550 · 2021: $760 · 2022: $944 · 2023: $1,010 · 2024: $885 · 2025: $642.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,449 · Education: $89.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,448.94 |
| Education | $89.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $954.64 | 2019-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $564.66 | 2019-2025 | Lifevest |
| Amgen INC. | $479.95 | 2019-2025 | Repatha, Repatha |
| Abbott Laboratories | $432.55 | 2020-2025 | Aveir, Merlin@Home |
| Pfizer INC. | $306.75 | 2020-2024 | |
| Novartis Pharmaceuticals Corporation | $285.60 | 2019-2024 | |
| Esperion Therapeutics, INC. | $263.31 | 2021-2024 | Nexletol |
| Edwards Lifesciences Corporation | $242.44 | 2023-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Astrazeneca Pharmaceuticals LP | $236.55 | 2019-2022 | |
| Boston Scientific Corporation | $195.49 | 2023 | Watchman Flx, Watchman Access System |
| Lexicon Pharmaceuticals, INC. | $192.02 | 2024 | Inpefa |
| Sanofi-Aventis U.S. LLC | $181.84 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $170.35 | 2019-2023 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $137.40 | 2024-2025 | Camzyos, Eliquis |
| Actelion Pharmaceuticals US, INC. | $124.03 | 2022-2025 | Uptravi, Opsumit |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $120.15 | 2022-2024 | (Ck4) Mcot, (5044) Mcot |
| Regeneron Healthcare Solutions, INC. | $103.24 | 2019 | |
| Medtronic, INC. | $97.99 | 2021-2025 | Micra |
| Abiomed | $97.94 | 2023-2024 | Impella |
| Biotronik INC. | $92.80 | 2019-2025 | Acticor 7 Vr-T Dx |
| Heartflow, INC. | $47.98 | 2023 | Ffrct |
| Baxter Healthcare | $44.99 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Merck Sharp & Dohme LLC | $36.39 | 2024-2025 | Verquvo |
| Chiesi USA, INC. | $29.50 | 2022-2023 | Kengreal, Cleviprex |
| Eagle Pharmaceuticals, INC. | $29.15 | 2023 | |
| Atricure, INC. | $26.60 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.38 | 2022 | |
| Shockwave Medical, INC | $16.71 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $15.79 | 2024 | Arcalyst |
| Genentech USA, INC. | $12.67 | 2019 | |
| Elutia, INC. | $12.50 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Hardwick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.